Metal-Ion STING Nanoparticles for Tumor-Targeted Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current human STING agonists have poor pharmacokinetics and cause serious side effects, limiting their systemic application in cancer immunotherapy, while 'cold tumors' are less responsive to immune checkpoint blockades due to low inflammatory responses and deficient T cell infiltration.
Innovation Solution
Formulating CDNs into nanoparticles with Zn2+ and lipid vesicles, or calcium phosphate and PEI-PEG copolymers, enhances STING activation and tumor targeting, and using specific metal ions like Mn2+ or Co2+ to improve immune response efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecular weight STING agonists are used, then they can activate the STING pathway, but they have poor pharmacokinetics and cause severe side effects due to widespread distribution
Solution Approach 1:
The patent divides the STING agonist into nanoscale particles (50-500 nm) that can be selectively accumulated in tumor tissues through the enhanced permeability and retention effect, thereby segmenting the distribution pattern to reduce widespread exposure while maintaining therapeutic activity
Solution Approach 2:
The patent introduces nanoparticles as intermediary carriers that transport STING agonists to target tissues, mediating between the systemic circulation and tumor sites to achieve selective delivery and reduce off-target effects
2Reliability
If STING agonists are administered systemically, then they can activate immune response, but they have poor tumor targeting and high toxicity
Solution Approach 1:
The patent imparts local quality to the STING agonist formulation by incorporating it into nanoparticles with specific surface properties and size characteristics that enable selective accumulation in tumor tissues, creating a localized high-concentration zone that activates immunity while minimizing systemic toxicity
Solution Approach 2:
The patent changes the physical parameters of the STING agonist from small molecules to nanoscale particles with controlled size (50-500 nm), surface charge, and composition, thereby altering its pharmacokinetic behavior to achieve improved tumor targeting and reduced toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle formulations increase cancer cell uptake, reduce toxicity, and induce robust immune responses against tumors, leading to improved treatment outcomes and long-term immunity against relapse.
Implementation Method 1
nanoparticles associated with CDNs are associated with one or more metals or metal ions, such as zinc, manganese, or cobalt
Implementation Method 2
which stabilize STING agonists, enhance cancer cell uptake, and provide pH-sensitive release
Data Source
AI summary
This disclosure provides compositions and methods for stimulating the innate immune response in a subject with agents capable of stimulating an innate immune response in a subject upon administration to the subject (e.g., damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)). In particular, the present invention is directed to compositions of DAMPs/PAMPs and metals ions, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).